Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key

Executive Summary

AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.

Advertisement

Related Content

AstraZeneca Immuno-Oncology Hopes Buoyed By Tremelimumab
Eisai’s Lenvima Will Face Off Against Nexavar In Thyroid Cancer
With Oncology Drugs On The Way, AstraZeneca Sets The Stage For New Launches
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
Tandem Approval Brings GSK’s Tafinlar And Mekinist To A Market Ready To Test Combinations
AstraZeneca/MedImmune Synergies An Advantage In Immune-Mediated Cancer Therapies
AstraZeneca’s MEK Inhibitor Boosts PFS, But Misses Overall Survival Endpoint In Lung Trial
Genentech Likely To Wait For Survival Data For U.S. Filing Of Avastin In Ovarian Cancer
AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel